Evidence map›Paper›PMID 41276733›Full record

ReviewDiscover nano2025

Theranostics in the management of colorectal cancer.

Gowtham Menon, Thejaswini Anandan, Sakshi Maruti Kolage, Sarath Chandra Shenoy, Onkar Kacharu Lohakare, Akshata Sanjay Ahire, Deepu Ravindran

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gowtham MenonDepartment of Pharmaceutics, Sanjivani college of Pharmaceutical Education and Research, Savitribai Phule Pune University, Kopargaon, Maharashtra, 423601, India. gowthammphd@gmail.com.
Thejaswini AnandanDepartment of Pharmaceutics, Sanjivani college of Pharmaceutical Education and Research, Savitribai Phule Pune University, Kopargaon, Maharashtra, 423601, India.
Sakshi Maruti KolageDepartment of Pharmaceutics, Sanjivani college of Pharmaceutical Education and Research, Savitribai Phule Pune University, Kopargaon, Maharashtra, 423601, India.
Sarath Chandra ShenoyDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Govt. Medical College, Pariyaram, Kannur, Kerala, 670503, India.
Onkar Kacharu LohakareDepartment of Pharmaceutics, Sanjivani college of Pharmaceutical Education and Research, Savitribai Phule Pune University, Kopargaon, Maharashtra, 423601, India.
Akshata Sanjay AhireDepartment of Pharmaceutics, Sanjivani college of Pharmaceutical Education and Research, Savitribai Phule Pune University, Kopargaon, Maharashtra, 423601, India.
Deepu RavindranDepartment of Pharmacology, Rajiv Gandhi Institute of Pharmaceutical Sciences and Research, Thrikaripur, Kasargod, Kerala, 671310, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is one of the most common causes of hospital cancer morbidity and mortality in the world with more than 1.9 million new cases and almost one million deaths annually based on GLOBOCAN 2022. Although there are improvements in surgery, chemotherapy and immunotherapy, the existing treatment regimens are usually restricted by systemic toxicity, multidrug resistance, and late diagnosis. Such dilemmas will require the invention of more accurate and comprehensive methods of diagnosis and treatment.

objectiveThe objective of the review is to critically assess the application of theranostics that is, therapeutic and diagnostic modalities in the management of colorectal cancer; more so nanotechnology-based systems, molecular imaging and even targeted therapies.

methodsA search of the literature was conducted in PubMed, Scopus, Web of Science, and Google Scholar in the publications published starting in January 2020 until May 2025. Articles concerned with nanotechnology-based theranostic systems, molecular imaging modes, and targeted therapy of colorectal cancer were considered. Non-English and non-integrated diagnostic or curative researches were gone.

Indexed as

Clinical translationColorectal cancer (CRC)Molecular imagingNanotechnologyPrecision oncologyTargeted therapyTheranostics

Identifiers

PMID41276733
PMCPMC12640886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.